Results 1 to 10 of about 25,647 (169)

Voriconazole pharmacogenetics [PDF]

The Lancet, 2021
Nicolas, Pallet, Marie Anne, Loriot
openaire   +2 more sources

Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database

Scientific Reports
Voriconazole is a second-generation azole used to treat serious fungal infections. Visual hallucinations constitute a representative adverse event caused by voriconazole. However, its mechanism of action remains unclear. In patients with schizophrenia or
Hideo Kato, Chihiro Shiraishi, Mao Hagihara, Hiroshige Mikamo, Takuya Iwamoto   +4 more
doaj   +1 more source

Amphotericin B May Decrease the Serum Level of Voriconazole: A Case Report and Brief Review of Literature

Infection and Drug Resistance, 2022
Zhen Hu, Huaying Zhou Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People’s Republic of ChinaCorrespondence: Huaying Zhou, Department of Infectious Diseases, The Second Xiangya ...
Hu Z, Zhou H
doaj  

Myelodysplastic syndrome-like response after voriconazole treatment of systemic lupus erythematosus complicated with fungal infection: a case report

Frontiers in Medicine, 2023
BackgroundVoriconazole is mainly used to treat progressive and potentially life-threatening infections in immunocompromised patients. The adverse drug reactions related to voriconazole are varied. In some rare cases, the use of voriconazole can result in
Guang-Liang Xie, Xiao-Su Wang, Ling-Yan Hu, Yi Wang, Xiangchen Gu, Xiangchen Gu, Xiangchen Gu, Yan-Qiu Xu   +7 more
doaj   +1 more source

A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model

Journal of Translational Medicine, 2018
Background Invasive pulmonary aspergillosis (IPA) is a life-threatening disease in immunosuppressed patients. Voriconazole is commonly used to prevent and treat IPA in the clinic, but the optimal prophylactic antifungal regimen is unknown.
Taotao Wang, Tao Zhang, Ti Meng, Ying Li, Lu Chen, Qianting Yang, Haiyan Dong, Jin’e Lei, Limei Chen, Yalin Dong   +9 more
doaj   +1 more source

Plasma concentration of voriconazole under concomitant use of nirmatrelvir/ritonavir in patients with COVID-19: a multicenter retrospective study

Frontiers in Pharmacology
BackgroundThe concomitant use of nirmatrelvir/ritonavir and voriconazole is generally contraindicated in clinical practice because of drug‒drug interactions (DDIs).
Hao Shi, Xuan Zhang, Qihui Kong, Lingyan Yu, Zhenwei Yu, Zhenwei Yu, Zhenwei Yu   +6 more
doaj   +1 more source

A case report of drug–drug interaction between voriconazole and simnotrelvir/ritonavir

Frontiers in Antibiotics
Co-administration of simnotrelvir/ritonavir with voriconazole should be avoided, as stated in the product insert of simnotrelvir/ritonavir, due to the anticipated decrease in the plasma concentration of voriconazole.
Tingting Chen, Qingquan Zhang
doaj   +1 more source

Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis

Frontiers in Pharmacology
Voriconazole is a broad-spectrum triazole antifungal agent. A number of studies have revealed that the impact of C-reactive protein (CRP) on voriconazole pharmacokinetics was associated with the CYP2C19 phenotype. However, the combined effects of CYP2C19
Jing Ling, Xuping Yang, Lulu Dong, Yan Jiang, Sulan Zou, Nan Hu   +5 more
doaj   +1 more source

Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A systematic review and meta-analysis.

PLoS ONE, 2020
BackgroundChronic pulmonary aspergillosis (CPA) requires prolonged treatment with itraconazole or voriconazole. However, adverse events (AEs) are common with the use of these agents, with the need to discontinue the offending drug in a significant ...
Ronald Olum, Joseph Baruch Baluku, Andrew Kazibwe, Laura Russell, Felix Bongomin   +4 more
doaj   +1 more source

Voriconazole‐Associated Periostitis: New Insights into Pathophysiology and Management

JBMR Plus, 2022
Voriconazole‐associated periostitis (VAP) is an underrecognized and unpredictable side effect of long‐term voriconazole therapy. We report two cases of VAP occurring in the post‐transplant setting: a 68‐year‐old lung transplant recipient who required ...
Michael J Bennett, Matthew I Balcerek, Edward AD Lewis, Roland LL Zhang, Caroline Bachmeier, Siok Tey, Steven Faux, Laila Girgis, Jerry R Greenfield, Syndia Lazarus   +9 more
doaj   +1 more source